{"id":"av-mel-1","_chembl":{"chemblId":"CHEMBL3939716","moleculeType":"Small molecule","molecularWeight":"415.41"},"modality":"Small molecule","_dailymed":null,"mechanism":{"explanation":"The vaccine uses dendritic cells derived from the patient's own immune system, which are loaded with tumor antigens from the patient's melanoma. These activated dendritic cells are then reintroduced to stimulate a targeted immune response against melanoma cells.","oneSentence":"AV-MEL-1 is an autologous dendritic cell-based cancer vaccine that activates the immune system against melanoma tumor antigens."},"_scrapedAt":"2026-03-28T04:57:12.410Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123674,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"pembrolizumab","brand":"Keytruda","company":"Merck","rationale":"PD-1 inhibitor approved for melanoma treatment"},{"name":"nivolumab","brand":"Opdivo","company":"Bristol Myers Squibb","rationale":"PD-1 inhibitor approved for melanoma"},{"name":"ipilimumab","brand":"Yervoy","company":"Bristol Myers Squibb","rationale":"CTLA-4 inhibitor approved for melanoma"}],"description":"AV-MEL-1 is an investigational cancer vaccine developed by Aivita Biomedical for the treatment of melanoma. The therapy is currently in Phase 1 clinical development, representing a personalized immunotherapy approach designed to stimulate the patient's immune system to recognize and attack melanoma cells.","indications":{"approved":[{"status":"investigational","condition":"Melanoma","patientPopulation":"Adult patients"}]},"trialDetails":[{"nctId":"NCT03743298","phase":"PHASE1","title":"Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma","status":"RECRUITING","sponsor":"Aivita Biomedical, Inc.","startDate":"2021-04-21","conditions":"Metastatic Melanoma","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"AV-MEL-1","genericName":"AV-MEL-1","companyName":"Aivita Biomedical, Inc.","companyId":"aivita-biomedical-inc","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}